Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Asaf Maoz, M.D.

Concepts (113)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neoplasms, Squamous Cell12021960.770 Why?
ras Proteins1201710600.400 Why?
Ovarian Neoplasms4202048380.370 Why?
Troponin T120157540.360 Why?
Proto-Oncogene Proteins p21(ras)1201716920.340 Why?
Tumor Microenvironment3202435860.340 Why?
Macrophages1202356550.330 Why?
Colorectal Neoplasms3202367730.280 Why?
Protein Kinase Inhibitors2201955350.270 Why?
T-Lymphocytes12021101800.230 Why?
Lung Neoplasms32024131020.210 Why?
Brain Ischemia1201532650.190 Why?
Fanconi Anemia Complementation Group Proteins120201000.180 Why?
RNA Helicases120201420.180 Why?
Ketotifen12019210.170 Why?
Chalazion12019130.170 Why?
Histamine H1 Antagonists120191000.160 Why?
Microsatellite Repeats120208020.160 Why?
Membranes, Artificial120193780.150 Why?
Conjunctivitis120191580.150 Why?
Neoplasms22023216830.150 Why?
Histocompatibility Antigens Class I1202313660.150 Why?
Antineoplastic Agents22019136950.150 Why?
Clinical Trials, Phase II as Topic120196290.150 Why?
Cystadenocarcinoma, Serous120204500.140 Why?
Pancreatic Cyst120203680.140 Why?
Clinical Trials, Phase III as Topic120198410.130 Why?
Neoplasms, Second Primary1202310610.130 Why?
Gastroenterology120205360.120 Why?
Stroke1201599810.110 Why?
Disease Susceptibility1201917820.110 Why?
Neoplasms, Glandular and Epithelial120164840.100 Why?
Thrombocytopenia1201911790.100 Why?
Neoplasm Staging32020110310.100 Why?
Renal Dialysis1201917860.090 Why?
Guideline Adherence1202022660.090 Why?
Antineoplastic Combined Chemotherapy Protocols22020115240.080 Why?
Lymph Nodes1201934740.080 Why?
Disease Progression22021132840.080 Why?
Humans1820247443430.070 Why?
Crohn Disease1201923030.070 Why?
Carcinoma, Non-Small-Cell Lung1202452210.060 Why?
Multiple Myeloma2202051810.060 Why?
Gene Frequency2202335880.060 Why?
Proto-Oncogene Proteins1201745540.060 Why?
Female1020213801940.050 Why?
Pancreatic Neoplasms1202052560.050 Why?
Prognosis22020290630.050 Why?
Frameshift Mutation120233990.050 Why?
Disease Models, Animal12019180290.050 Why?
Cell Line, Tumor12017166890.050 Why?
Lost to Follow-Up120201050.040 Why?
Spain120204650.040 Why?
Histocompatibility Antigens Class II1202314750.040 Why?
Cricetulus120208160.040 Why?
Sterilization120191330.040 Why?
Phthalazines120203630.040 Why?
HLA Antigens1202313810.040 Why?
Aged, 80 and over32020577760.040 Why?
Disease-Free Survival2202068950.040 Why?
CHO Cells1202014060.040 Why?
Ophthalmic Solutions120193170.040 Why?
Carboplatin120208010.040 Why?
Middle Aged720202133830.040 Why?
Male620213501180.040 Why?
Microsatellite Instability120206840.040 Why?
Sulfones120194370.040 Why?
Heterozygote1202328040.040 Why?
Platelet Count120197810.040 Why?
Mutation22020297860.030 Why?
Drug Synergism1202017920.030 Why?
SEER Program1202015080.030 Why?
Incidental Findings120206890.030 Why?
Aged520201632800.030 Why?
Lymphocytes, Tumor-Infiltrating1202010380.030 Why?
Receptors, Antigen, T-Cell1202325400.030 Why?
Cisplatin1202016620.030 Why?
BRCA2 Protein120197940.030 Why?
BRCA1 Protein1202011490.030 Why?
Propensity Score1202017810.030 Why?
PTEN Phosphohydrolase1201911420.030 Why?
Tumor Suppressor Protein p531202429480.030 Why?
Minority Groups1202012230.030 Why?
Polymers1201916210.030 Why?
Case-Control Studies22020217460.030 Why?
Amyloidosis120197950.030 Why?
Chemotherapy, Adjuvant1202034790.030 Why?
Breast Neoplasms12019208220.030 Why?
Retrospective Studies42020774490.020 Why?
Biocompatible Materials1201917360.020 Why?
Animals220201687570.020 Why?
Drug Design1201610760.020 Why?
Cell Survival1202058820.020 Why?
Piperazines1202024880.020 Why?
Neoadjuvant Therapy1202027280.020 Why?
Molecular Targeted Therapy1202027270.020 Why?
Immunotherapy1202344450.020 Why?
Survival Rate12020127880.020 Why?
Proportional Hazards Models12020123540.020 Why?
Healthcare Disparities1202031580.020 Why?
Cell Proliferation12020104810.020 Why?
Patient Selection1201642150.010 Why?
Age Factors12020183700.010 Why?
Practice Guidelines as Topic1202072790.010 Why?
Health Services Accessibility1202051370.010 Why?
United States22020698720.010 Why?
DNA-Binding Proteins1201996480.010 Why?
Adult320202140550.010 Why?
Treatment Outcome22019631140.010 Why?
Follow-Up Studies12020390500.010 Why?
Neoplasm Recurrence, Local1201692390.010 Why?
Cohort Studies12020405610.010 Why?
Genetic Predisposition to Disease12019174460.010 Why?
Maoz's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (113)
Explore
_
Co-Authors (7)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2024 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.